upstream and downstreamaxichrom™ columns are employed. these columns with intelligent packing –...
TRANSCRIPT
-
Upstream andGE Healthcare
DownstreamIssue 2 • September 2009
New tools for process development – PreDictor™ plates, HiScreen™ columns and ÄKTA™ avant system
AxiChrom™ – removing column handling from the critical path
Expanding the ReadyToProcess™ platform
-
In this issue
3. Achieving operational efficiencyAs the biopharma industry matures, the drive to find and implement a broad range of operational improvements continues to intensify. New working methods and tools that focus on raising quality, reducing waste, and shortening cycle times are growing in importance.
6. High-throughput process development for increased process understandingThe FDA recent initiative encourages better process understanding to achieve robust, high-productivity biopharmaceutical manufacturing processes. PreDictor™ 96-well plates enable the parallel screening of process conditions and the characterization of a large experimental space. Further optimization studies on prepacked HiScreen™ columns can be run on ÄKTA avant system.
10. ÄKTA™ avant system with UNICORN™ 6 accelerates process developmentOur new ÄKTA avant chromatography system enables the development of scalable and robust chromatographic processes in the shortest amount of time. Increased productivity will shorten time-to-market and time-to-publish, and also provide cost savings.
13. ÄKTA ready system adds flexibility to your manufacturingThe ReadyToProcess™ platform speeds up processes by eliminating the need to establish and validate time-consuming procedures like cleaning. ÄKTA ready chromatography system further improves on this concept by introducing a completely replaceable liquid flow path for greater flexibility.
16. Increasing capacity through reduced cleaning and rapid changeoverContract manufacturers are constantly seeking better ways to maintain tight, multi-product production schedules and increase capacity. CMC Biologics in Denmark achieved both goals with the help of single-use products from the ReadyToProcess platform.
20. AxiChrom™ column platform takes column packing off the critical pathIntelligent Packing promoting optimally packed columns, guidance through operation and maintenance, as well as predictable scalability have simplified column handling at all scales from process development to full scale-production.
22. Evaluating filter cleaning conditions using ÄKTAcrossflow™
To improve both reliability and cost-efficiency in an NaOH-based cross-flow filtration cleaning protocol, plasma fractionator CSL Bioplasma of Australia simulated a revised protocol on ÄKTAcrossflow system. What would normally take months was accomplished in a few days, providing valuable data that supported adding sodium hypochlorite to the cleaning protocol.
26. When tailor-made is the best purification solutionFor some applications, custom designed media can be the swiftest way to a robust and economic process. Through collaboration, GE Healthcare can offer several specialized media.
28. Fifty years of Sephadex™ – a springboard to innovationThis year GE Healthcare celebrates the golden jubilee of Sephadex. Gel filtration with Sephadex revolutionized the separation of biological molecules and laid the foundation to many developments within the life sciences.
-
Achieving operational efficiencyOperational excellence – reducing time and costs of development and manufacturing – is the goal of all biopharmaceutical producers. Achieving this in practice is as likely to emerge from new working methods and cultures, as well as from new products and technologies. Lean and Six Sigma are two key approaches. With their origins in the 20th century, their significance is highly relevant to today’s manufacturing industry.
-
4 Upstream and Downstream • Issue 2
In the last five years or so, the biopharma industry has encountered many new challenges. While still facing the usual demands for revenue and profit growth, increasing pressure on
drug prices, the ongoing re-evaluation of many therapies, rising
operational costs and the management of substantial financial
investment risks need to be dealt with. The industry is maturing in
many ways, and while new technologies and markets bring new
opportunities for growth, other pressures, like the introduction
of biosimilars, will continue to drive the need for operational
improvements across the entire industry.
Many responses to these challenges have been tried, including
consolidation. New technologies and approaches, such as the use
of platform processes, process analytical technology (PAT), and
disposables can all help to reduce time and costs of development
and manufacturing. We are also seeing the adoption of new
working methods that focus on quality, reduction of waste and
cycle times, and cultural acceptance of change. These generic,
non-product specific but very effective methods are often grouped
under the umbrella of Operational Excellence programs.
Operational excellence describes the goal of achieving superior
yields, lead time and throughput whilst eliminating waste. It is
a systematic approach to attaining world-class performance
in productivity, quality and delivery of services and/or goods.
Effective tools for achieving this include Lean and Six Sigma.
Tools
Lean relentlessly targets eight types of waste in a process. A Value
Stream Analysis reveals that typically between 80 and 90% of a
process is composed of non-value adding activities. In targeting
these, lean can drastically reduce lead time. Additionally, removing
waste contributes to increasing quality and process speed. (see Lean
insert). Another tool is Six Sigma, which focuses on reducing variation
and defects, and hence improving quality. Six Sigma can be applied
to both Value Adding and Non-Value Adding steps in a process.
Lean can be applied across the whole biopharmaceutical value chain,
from research through development to full-scale manufacturing.
It can be used to find ways to create better process flow, reduce
downtime and stoppages, and reduce non-productive activities
such as changeover time between production campaigns, cleaning
procedures, or preparation of equipment and process buffers.
Solutions for efficiency
GE Healthcare can support its customers with lean-enabling
technologies and solutions to meet the demand for improved
process efficiency. High Throughput Process Development (HTPD)
on PreDictorTM 96-well plates and with Assist evaluation software,
allow the identification of the most appropriate chromatography
conditions for a process by running experiments in parallel in a
very short time, helping to define the design space and limits of
operation. See page 6.
A next step is then to perform optimization studies on HiScreen
columns run on ÄKTA™ avant system. See page 10.
Single-use solutions like the ReadyToProcess™ platform offer
the manufacturing agility that is required to switch quickly
between production campaigns. In comparison with conventional
processes, where time is spent packing, cleaning and validating
the column and liquid flow path, with ReadyToProcess this is
removed.
Even when using traditional chromatography columns, packing
can be removed from the critical path in a process when
AxiChrom™ columns are employed. These columns with Intelligent
Packing – preprogrammed packing methods – provide close to
perfect packing every time and cut out wasteful repacking time.
Their design also provides easy access for service, eliminating
many of the cumbersome dismantling steps of more traditional
columns, see page 13.
Fig 1. The biopharmaceutical industry faces many pressures - but there are opportunities to be taken.
Crowded markets• Fewer blockbusters
• Redundant medicines
Cost pressure• Reimbursement
• Biogenerics
Maturing Industry• 14% annual growth
• >25 approved MAbs
New opportunities• New molecules
• Vaccines
-
10.911.8
19.2
37.4
0
5
10
15
20
25
30
35
40
Classic process Protein A update Protein A 3-stepmodel process
Protein A 2-stepmodel process
Dow
nstr
eam
cos
t con
trib
utio
n (U
SD/g
)
0
20
40
60
80
100
120
DSP
pro
cess
tim
e (h
)
Working volume: 10,000 LTiter: 5 g/LYield: 79% Sepharose™
Fast Flow media
MabSelect SuRe/Capto™ S/
Capto Q
MabSelect SuRe™/Sepharose Fast Flow
MabSelect SuRe/Capto adhere
Fig 2. Process economy gains – use of modern media: combined effect of capacity, flow and lifetime. The assumptions and calculations used for this graph are from a model study performed at GE Healthcare. Costs relating to the facility, equipment and upstream processes are excluded from the calculations, but all downstream-related labor, media, membranes, filters and buffer costs are included.
The roots of Lean go back to the turn of the 20th century. Sakichi Toyoda, founder of the Toyota Corporation, developed his
textile manufacturing business so that the factory was largely automated and error-proofed to stop any abnormalities and allow
immediate rectification with little or no waste.
Further information1. Jagschies, G. Where is Biopharmaceutical Manufacturing Heading. BioPharm Int. 21, 72–88 (2008).
2. Kelley, B. Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations, Biotechnol. Prog. 23, 995–1008 (2007).
When replacing the capture step in a classic MAb process with
MabSelect, process time is reduced and specific costs ($/g) are
lowered by approximately 50%. Completely changing to recently
developed media technology reduces the process time to 2 days
and the costs to just above 30% of the original level (“model
process”). This translates into a 2–3 fold productivity increase
for the corresponding original downstream process, partly by
enabling many more batches per year.
The development of advanced media has positively impacted
chromatography capabilities. This is especially true for Protein A
media where the introduction of higher capacity and more stable
media offers simplified CIP regimes and longer working lives.
Novel ion exchangers with higher capacities, increased volume
throughputs, and multimodal selectivities can also help shorten a
process from three to two steps. Removing a process step whilst
achieving the same quality result (as is possible with MabSelect
SuRe and Capto adhere in the purification of monoclonal
antibodies) is a significant efficiency improvement.
Operational excellence
The challenges facing biopharmaceutical production over the next
few years include flexible development and manufacturing, multi-
product facilities, and rising costs. GE Healthcare continues to work
closely with the industry to supply solutions that drive down costs,
improve productivity and yields, and provide manufacturing agility
to achieve the ultimate goal of operational excellence. In this issue
of Upstream Downstream we present some of the developments
that will help meet these challenges.
Lean can be broadly described through main five principles:
• Define value – from the end-user’s point of view.
• Identify the value stream – develop an understanding of how value flows to the product/service/person/object that is moving through the process.
• Establish flow – create a situation where the product/service/person/object moving through the process does so with no interruptions or issues.
• Examine ‘pull’ from the end-user – until something needs doing from that perspective, don’t do it .
• Describe perfection – it’s the aim that can never be achieved, but processes will be improved by trying.
The main focus of Lean-enabling technologies is to reduce waste. Below is a list of the most common causes of waste. The figure below shows where time and money can be saved when implementing operational excellence tools:
After
Before
Lean attacks waste here
Six Sigma attacks variation
Work: Value added time
Wait time/waste:Non-value added time
Cycle time or lead time
Cycle time or lead time
• Over-production
• Transportation
• Motion
• Waiting
• Over-processing
• Inventory
• Defects
• Underutilization
Modern media
Figure 2 illustrates how utilising second generation chromatography
media can change the performance of the whole downstream process.
Principle of Lean
-
6 Upstream and Downstream • Issue 2
Process development using PreDictor plates and Assist software introduces a new way of working that can replace the laborious experiments that are the norm today. PreDictor plates can help generate a large amount of data, improve process understanding, and lay the foundation for robust manufacturing.
High-throughput process development for increased process understanding
PreDictor™ plates are pre-filled with media from the Capto™, MabSelect™, and Sepharose™ families. They are available filled with a single medium or multiple media.
-
PreDictor™ 96-well plates and Assist software
for screening
ÄKTAavant 25, UNICORN 6, and HiScreen columns
for optimization
ReadyToProcess™/ AxiChrom™ columns for scale-up and production
Fig 2. PreDictor plates can be used in automated workflows such as with the Tecan Freedom EVO™ workstation.
Finding optimal conditions for a downstream purification process early on is critical for a highly productive and robust manufacturing process. The recently introduced FDA initiative
“Quality by Design” may also impact process development work
because of the higher degree of process understanding needed.
One way to gain this understanding is to characterize a large
experimental space and then perform more detailed studies. An
efficient approach is high throughput process development (HTPD)
using PreDictor 96-well plates.
HTPD is a new way of working that shortens process development
time and increases the amount of information available, while
keeping sample consumption low. Chromatographic conditions
are evaluated in a rapid, parallel manner using 96-well filter
plates. Parallel screening in a miniaturized format allows higher
throughput, lower sample consumption, and can generate a
large amount of data that facilitates the design of more robust
manufacturing processes.
Figure 1 illustrates the conceptual workflow for process
development. Following screening for best chromatographic
conditions on PreDictor plates, fine-tuning is carried out on
HiScreen columns and ÄKTA avant system. Scale-up can then be
done under conditions that give a robust manufacturing process.
PreDictor platesPreDictor plates are disposable, 96-well filter plates made of
polypropylene and polyethylene. Each well has a total volume
of 800 µl, and each plate is prefilled with a defined amount of
chromatography medium per well. Plates are available filled with
a single medium or different media from the Capto, MabSelect
and Sepharose families. They are supplied in packs of four, which
is sufficient to perform 128 tests in a study done with triplicates.
PreDictor plates can be used in automated workflows using robotic
systems (Fig 2), or operated manually using multi-channel pipettes.
Fig 1. Conceptual visualization of a workflow for process development. PreDictor plates and Assist software (left) allow screening of a large experimental space to identify the sub-space that is favorable with respect to one or several defined responses. Once this subspace has been found, optimization may be done on HiScreen™ columns and ÄKTA™ avant system (middle). Scale-up can then performed under conditions in which a robust process can be operated, for example on ReadyToProcess™ or AxiChrom columns (right).
-
8 Upstream and Downstream • Issue 2
Type of study
Experimental design
Plate data
Replicate plot
Plate layout
Experimental protocol
Mass balance
Adsorption isotherm
Response curve
Response surface
Lab instructions
Experimental setup Data management Data analysis
0
50
100
150
200
Binding capacity (mg/ml)
Wells
Fig 5. Assist software offers a range of data analysis and presentation options, including contour plots.
Removal of liquid can be done by either centrifugation or vacuum.
The plates provide consistent well-to-well and plate-to-plate
performance regardless of mode of operation and ensure high
reproducibility of results (Fig 3).
Assist software for PreDictor plates
Assist software supports the set-up of experiments and evaluation
of data generated from PreDictor plates. This software helps
the user in experimental set-up, data management, and data
evaluation. Assist software introduces standardized procedures
that guide the user through the experimental workflow with
PreDictor plates, from selection of study to evaluation of results.
Figure 4 presents an overview of the typical workflows provided by
Assist software.
Fig 3. Reproducibility of capacities for chymotrypsin (60 min incubation) determined in a PreDictor Capto S plate containing 2 µl medium per well. The solid red line corresponds to the average value, dashed lines denote ± 2 standard deviations. Columns 1–12 on the PreDictor plate are denoted by the alternating colored bars, indicating the absence of any significant edge effects.
Fig 4. Assist software provides standardized workflows for experimental set-up, data management, and data analysis.
Figure 5 shows examples from a screening experiment that has
been evaluated using Assist software.
Screening conditions
PreDictor plates can be used to screen different parts of the
chromatographic cycle, for example determination of binding,
wash, and elution conditions. This can be done for different
chromatography media simultaneously using dedicated screening
plates, or more thoroughly using plates with a single medium.
The correlation between data obtained with PreDictor plates
and those obtained in column experiments is very good, which
makes the plates an excellent tool for initial screening of process
conditions. Figure 6 shows the results from screening for optimal
loading conditions for conalbumin on Capto S, with the same
experiment performed on PreDictor plates (Fig 6A) and in a packed
column (Fig 6B). The results show that non-traditional binding
behavior is captured equally well in the plate as in the column
experiment.
Adsorption isotherms
Adsorption isotherm describes the relation between the
concentrations of protein(s) in the liquid and solid phases at
equilibrium under a given set of experimental conditions. This
helps to understand and correctly describe what happens during
protein uptake under different conditions. PreDictor plates
dedicated to determining adsorption isotherms are also available.
These plates contain a single medium in all wells, but with different
volumes in different wells to allow rapid construction of isotherms.
-
180
140
160
100
120
60
80
20
40
Bind
ing
capa
city
(mg/
ml)
00 0.05 0.1 0.15 0.2
Ionic strength (M)
pH 4.75
pH 5.25
pH 4.25
160
140
120
100
40
20
60
80
00 0.05 0.1 0.15 0.2
pH 4.75
pH 5.25
pH 4.25
Dyn
amic
bin
ding
cap
acity
(mg/
ml)
Ionic strength (M)
20
10 2 3 4 5 Residence time (min)
DBC
hIg
G (m
g/m
l med
ium
)
30
40
50
MabSelect XtraMabSelect SuReMabSelect
500 300 150 cm/h
HiScreen columns – the next stepPrepacked HiScreen columns and ÄKTA systems such as the new
ÄKTA avant, are the natural step-up from PreDictor plates for
verification, or further process development studies on binding
capacity, robustness and resolution. Nineteen HiScreen columns
are currently available, packed with different media from the
MabSelect, Capto, and Sepharose families for the capture of
monoclonal antibodies, ion exchange, hydrophobic interaction,
and immobilized metal affinity chromatography.
The columns have 10 cm bed height and a small volume (4.7 ml) to
keep sample and buffer consumption low. If a greater bed height
is required, two columns can be connected in series to achieve a
20 cm bed.
Fig 6. Determination of loading conditions for conalbumin on Capto S. A) binding capacities at 60 minutes in PreDictor Capto S 2 µl plates. Error bars represent one standard deviation, based on triplicates. B) dynamic binding conditions at 10% breakthrough. Residence time 2 minutes, column Tricorn™ 5/100 (CV 2 ml).
Further information
Data File PreDictor 96-well plates and Assist software, Code No. 28-9258-39
Application Note Adsorption equilibrium isotherm studies using a high-throughput method, Code No. 28-9403-62
Handbook High-throughput process development with PreDictor plates Principles of operation, Code No. 28-9403-58
Brochure PreDictor platform and Tecan automation – efficient solutions for process development, Code No. 28-9403-60
Web www.gelifesciences.com/predictor
Fig 7. Comparison of dynamic binding capacity for hIgG on the three HiScreen columns for antibody purification.
More knowledge – less time
Parallel screening in a miniaturized format with Predictor plates
together with Assist software for experimental setup and data
evaluation represents a new way of working that can speed up
process development and thus time-to-clinic. By being better
able to define the limits of the process and gain an increased
understanding of the interaction of the variables, robust processes
can be defined in a shorter time and with greater reliability. These
new tools for high-throughput process development are a step
towards increasing efficiency.
A
B
HiScreen columns are available with different media for screening and optimization studies.
Application
In antibody purification capacity is one of the most important
parameters. HiScreen columns are a useful tool for verification
studies. In Figure 7, dynamic binding capacity was measured at three
different residence times for HiScreen MabSelect, HiScreen MabSelect
SuRe™ and HiScreen MabSelect Xtra™. For this monoclonal antibody,
HiScreen MabSelect Xtra showed the highest capacity.
-
10 Upstream and Downstream • Issue 2
Gathering more precise information in fewer experiments means that robust, high-quality processes take less time to develop. The resulting cost-savings increase overall processing productivity when scaling up. New ÄKTA avant 25 liquid chromatography system with UNICORN 6 control software now provides just such an opportunity via its built-in Design of Experiments (DoE) tool.
ÄKTA™ avant with UNICORN™ 6 accelerates process development
-
Increased productivity via more efficient method scouting and process development is a key feature of our new ÄKTA avant
25 preparative liquid chromatography system, with flow rates
up to 25 ml/min. The system, which comprises ÄKTA avant
instrumentation and specially-developed UNICORN 6 control
software, also offers greater security through column recognition
and individual column run history data, automatic on-line buffer
preparation, and easy protocol transfer during scale-up.
Flexible system for fast separations
As a complete solution for fast, high-quality protein separations,
ÄKTA avant extends the flexibility and reliability of the well-proven
ÄKTA design concept.
The instrument’s compact design offers easy access to the
working areas using a swivel foot. All valves, monitors and
columns are mounted on the wet side of the system, which has a
door and pump cover for safe, convenient handling during runs.
The buffer tray on top of the instrument provides a large storage
area for vessels and bottles. A versatile pull-out fraction collector,
temperature controlled to prevent local heating of samples, is
accessed via the front (Fig 1). The front also includes an interactive
instrument display panel that informs users of the current
instrument and method status. Runs can quickly be paused or
continued from this display. To ensure reliability, the system
performs self-diagnostic tests at appropriate intervals.
Fig 1. ÄKTA avant 25 fraction collector holds a wide variety of tube and deep well plate cassettes. Each type is automatically detected by a sensor and the correct rack configuration confirmed.
Fig 2. UNICORN 6 features a new graphical interface with task bar, customizable docking windows and object navigators.
New UNICORN 6 control software
Specially developed for use with ÄKTA avant 25, UNICORN 6
software enables users to achieve their process development
goals quickly and efficiently. It features a new graphical user
interface (Fig 2), an improved Method Editor, and the integrated
Design of Experiments (DoE) tool noted earlier. The Method
Editor contains all the instructions used for controlling the
chromatographic run. Its user-friendly interface with customizable
panes allows easy viewing and editing of the method and run
properties.
The added security assured by UNICORN 6 is provided by a Column
Logbook that tracks individual columns and column run data that
improves traceability, as well as BufferPro, an automatic on-line
buffer preparation that promotes rapid method optimization.
BufferPro includes several buffer systems and features an improved
algorithm. In addition, robust database storage improves data
security, integrity and access. Like previous versions of the software,
UNICORN 6 is FDA 21 CFR Part 11 compliant.
-
12 Upstream and Downstream • Issue 2
DoE – more precise information in fewer experiments
A key feature of ÄKTA avant 25/UNICORN 6 is the integrated DoE
function. DoE allows the maximum amount of information to be
obtained from a minimum number of experiments.
The traditional approach to determining optimal method
conditions is to vary one parameter, e.g. elution pH, at a time while
keeping the rest fixed. In contrast, DoE employs an organized,
statistical approach that varies all important process parameters
or factors simultaneously. Resulting response data automatically
generate validated statistical models that are used to predict
untested factor settings and produce contour maps that support
more robust method development (Fig 3).
DoE is an important step towards automating process development.
By including DoE experimental workflows as standard in UNICORN 6
software increases the productivity of process development.
In summary
The combination of ÄKTA avant 25 chromatography system
and UNICORN 6 control software gives process developers a
powerful tool to accelerate their work and be more confident
with the results obtained. The time and cost savings help improve
processing productivity. Online training for UNICORN 6 is also
available – see below.
UNICORN method Design input Design and scouting Run
• Definition of factors, factor types and settings
• Definition of objective for creating the design
Model evaluation Use of model for prediction and decisions
Fig 3. In DoE, multiple factors are varied simultaneously and the resulting data is used to generate a statistical model. The model is validated and used to produce maps that support process development.
-
ÄKTA™ ready system adds flexibility to your manufacturingÄKTA ready liquid chromatography system, part of the ReadyToProcess™ platform, operates with a novel, quick-change liquid flow path that adds considerable flexibility and time-savings to bioprocessing. The system is designed for process scale-up, and production for Phase I-III drug testing. It is seen here fitted with a ReadyToProcess column.
-
14 Upstream and Downstream • Issue 2
In the race to market, speed is needed to produce small quantities of product for clinical trials long before investing in large-scale
capacity. Apart from the desire to be first on the market, speed
is also critical when producing vaccines to counter epidemics
such as influenza. Today, such challenges are being addressed by
single-use platforms like ReadyToProcess. This growing platform
supports the need for speed and manufacturing flexibility.
ÄKTA ready, a chromatography system that operates with
disposable, quick-change flow paths, is the latest addition.
Quick turnaround
Cleaning is a task that usually consumes valuable production
time, especially when working to tight schedules with a diversity
of products on several production lines. ReadyToProcess products
speed processes by largely eliminating the need to establish and
validate cleaning procedures. Additionally, they reduce the risk for
cross-contamination. ÄKTA ready chromatography system helps
streamline processes by introducing a novel, fully-disposable flow
Kit . With these kits, system flow paths can be changed quickly
(downtime less than 1 hour), which saves considerable time.
Capital investment, start-up expenditure, as well as costs of labor
and consumables are also reduced.
Replaceable flow path
The system comprises a chromatography unit , UNICORN™
software and two separately available disposable flow kits: ÄKTA
ready Low Flow Kit for flows up to 170 L/h, typically columns less
than 20 cm in diameter, and ÄKTA ready High Flow Kit for flows
up to 510 L/h, columns typically over 20 cm in diameter, Table 2.
Each kit consists of three separate parts: an inlet manifold, pump
tubing and a Flow Kit for main flow path that includes sensors
and detection flow cells, Table 1. An installation test needs to be
performed when fitting a new flow path. This test is supported by a
UNICORN wizard.
Safe, robust and hygienic
ÄKTA ready system flow kits are manufactured under controlled
conditions and packed in a class ISO 8 clean room environment
using validated protocols. Pump tubing is autoclaved and other
flow kit parts are gamma-irradiated. The kits are double-packed to
protect against contamination.
To further promote process safety, each ÄKTA ready Flow Kit is
supported with extensive documentation and support plus a test
protocol for component and pressure testing.
The chromatography system itself is resistant to chemical agents
used in protein recovery, including buffer solutions for adsorption,
elution and washing, and to regeneration and cleaning solutions.
All material is of proven quality and traceable to the production
batch. Wetted materials are fully-biocompatible (USP class VI).
ÄKTA ready system is delivered with Validation documentation that
includes a functional test protocol.
Greater speed and flexibility
Designed for isocratic and step elution, ÄKTA ready system
brings many opportunities for improving the efficiency of
biopharmaceutical production.
More time is available for production (since cleaning and
sterilization steps as well as validation are removed) and
manufacturers running a large number of parallel projects have
the flexibility to easily switch to those have a better chance of
success. The speed at which production changes can be made,
plus the ability to work in a regulated environment, provides the
manufacturing agility that is needed today.
Table 2. System capacity
Volumetric flow rates 7.5–510 l/h High Flow Kit
3–175 l/h Low Flow Kit
Pump speed 340 rpm (100%) High Flow Kit
225 rpm (100%) Low Flow Kit
Max. pressure, peristaltic pump 4.0 bar
System pressure rating 5.0 bar (high-pressure flow path, upstream column)
2.0 bar (high-pressure flow path, downstream column)
0.95 bar (low-pressure outlet manifold)
0.6 bar (low-pressure inlet manifold)
Table 1. Sensor specifications
Sensor Acceptance range
Measurement error1
Pressure 0–5 bar g ±0.20 bar g
Flow (High Flow Kit)2 7.5–510 l/h ±5% actual value or ±0.75 l/h, whichever is greater
Flow (Low Flow Kit)2 3–175 l/h ±5% actual value or ±0.3 l/h, whichever is greater
Conductivity3 0–150 mS/cm ±5% Full scale
pH4 pH 2–12 ±0.2 pH at calibration temperature Drift: ±0.025 pH units/h (20°C, pH 4) Flow-rate sensitivity: ±0.1 pH unit
UV5 absorbance range
0.01–1.0 AU
Deviation from linearity ±5%
Temperature6 2°C to 40°C ±3°C
1 max. error, valid within acceptance range under recommended operation conditions 2 flow meter cells for High Flow Kit and Low Flow Kit are designed with different flow-path geometries 3 temperature compensation optional 4 temperature compensation not available 5 cell length: 1.8 mm ±0.2 mm 6 valid for max. temperature difference of 10°C between liquid and ambient temperature
-
ReadyMate™ DAC maintains secure connectivity upstream and downstream Typical uses of the ReadyToProcess™ platform include
aseptic cell processing as well as the aseptic clarification and
purification of vaccines, monoclonal antibodies, recombinant
proteins and plasmids.
To maintain secure links and sterile integrity throughout
such processes, ReadyMate Disposable Aseptic Connector
(DAC) devices provide simple, sterile connections between
upstream/downstream components and leak-proof seals of
plastic tubing.
Safe, single-use connections are made quickly and easily in
any environment and a flexible genderless design reduces
inventory. The validated closure mechanism uses standard
sanitary clamps (ISO 2852) or a disposable clamp to achieve
tamper-proof, lightweight connections.
ReadyMate DAC connectors are available in six connection
sizes: 1/4” (6.4 mm OD), 3/8” (9.5 mm OD), 1/2” (12.7 mm OD),
3/4” (19.1 mm OD), standard Mini TC (15.7 mm ID), and
standard TC (19.7 mm ID). All connectors are gamma
compatible and manufactured in compliance with current FDA
and ISO 9000-2000 GMP directions.
ReadyMate DAC connectors maintain secure links and sterile integrity between ReadyToProcess platform components both upstream and downstream.
One liter ReadyToProcess™ column formatThe ReadyToProcess range of prepacked, prequalified and
presantized columns has been extended with the addition of
the one liter size.
ReadyToProcess columns are designed for process scale-up,
and production for Phase I-III drug testing and are available
with a range of BioProcess™ media in sizes of 1, 2.5, 10 and
20 liters.
The columns can be used for the chromatographic separation
of various compounds, for example proteins, endotoxins,
DNA, plasmids, vaccines, and viruses.
-
16 Upstream and Downstream • Issue 2
Rinse samples TOC (Total Organic Carbon) Endotoxin Bioburden
Swab samples TOC
Visual inspection
Contract manufacturers work to tight schedules, producing multi-products on several production lines. Cleaning is a critical element that impinges on valuable production time. Upstream/Downstream talked with CMC Biologics in Denmark who have evaluated ReadyToProcess™ as a means of increasing uptime through eliminating some of the cleaning steps.
Increasing capacity through reduced cleaning and rapid change-over
CMC Biologics A/S (CMC), Denmark, a contract manufacturing organization, has a multi-product facility with several production
lines. It performs both microbial fermentation and cultivation of
mammalian cells in separate lines within the same facility. Efficient
cleaning procedures comprising verification, validation, evaluation
and documentation are central to its business.
CMC carried out a cleaning evaluation study comparing
conventional chromatography systems and columns with
products from the ReadyToProcess platform. The evaluation
compared the man-hours required for a typical cleaning process
between campaigns at their facility. The study used both
modelling and data from their normal routines. Columns and
systems were of comparable dimensions. This article is based on
the report by Kristoffer Rundenholm Hansson, Manager of Cell
Culture Purification, and Sandeep Kristiansson, Principal Scientist ,
Cell Culture Purification.
Cleaning documentation
In a multi-product facility, several products are processed using
the same equipment. Cleaning and cleaning validation is thus a
critical step in facility-changeover between production campaigns.
In some campaigns where the number of batches produced for
each product is low and the cleaning validation not finalised, a
cleaning verification is performed. Both cleaning verification and
cleaning validation provide proof that the equipment is properly
cleaned before a new production run is initiated. Both have
predefined acceptance limits for several cleaning parameters
and both are performed according to an established protocol.
Following cleaning verification or validation a final report is
issued; this report must be approved for all equipment used in a
production campaign prior to production start .
Cleaning procedures at CMC
Cleaning is performed before, during and after a campaign. If
equipment is new, then the first task is to write a cleaning protocol.
For existing equipment, a standard cleaning protocol is usually
followed. Preparations before the start of a campaign include setting
up systems, installing tubing and system inlets and outlets, and
cleaning before use. Similarly, the column will require cleaning of the
tube, packing with media, HETP testing, and cleaning of media.
Before production can begin, a campaign equipment rationale is
written for all equipment. This document provides an evaluation of
the predefined acceptance limits to determine whether they are
adequate with respect to the total equipment surface area in the
campaign, the estimated number of doses to be produced, and
the daily dose size for both previous batches and for the planned
batch. This is an important procedure for a multi-product facility
as these factors vary from campaign-to-campaign. The risk of
product carry over is calculated, evaluated and documented in
the campaign equipment rationale. With production underway,
cleaning is performed between batches.
At the end of a campaign, a cleaning verification is carried out. This
involves following a prescribed cleaning protocol that defines the
parameters used to verify cleaning. At CMC, these parameters are:
-
Equi
pmen
t set
up
Batch production
Between batch cleaning
Cleaning verification/validation
Batc
h pr
oduc
tion
Cleaning
Day1
Day2
Day3
Day4
Day5
CIP, Rinsesampling
Swabsampling
Preliminarybioburden results
Finalbioburden results
Timing Step eliminatedEstimated time needed in a single-use
Activity Comment
process
Before use of Produce cleaning 1 daynew equipment protocol
Before start of Campaign 0.5 day Includes QAa campaign equipment review rationale
Before start of Equipment set up 0.5 daya campaign
Before start of Cleaning before 0.5 day Includesa campaign use preparation of CIP solutions
During a Cleaning 1 daycampaign between lots
After a campaign Preparation of 1–2 hours Training in protocol, sampling wash of sampling glasses
After a campaign Cleaning after use 0.5 day
After a campaign Rinse sampling, 1 day Includes drain of system preparation of and swab sampling CIP solutions
After a campaign QC assays 0.5–1 day Two persons half a day
After a campaign Cleaning report 1 hour Includes review
Step eliminatedEstimated time in a single-use
Timing Activity
Commentneeded
process
Before use of Produce cleaning 1 day Only for newnew equipment protocol equipment The cleaning protocol is reused
Before start of Campaign 0.5 day Includes QAa campaign equipment review rationale
Before start of Equipment set up 0.5 daya campaign
Before start of Cleaning before 0.5 day Includesa campaign use preparation of CIP solutions
Before start of Column packing 1 day Includesa campaign and HETP test preparation of packing and HETP solutions
During a Cleaning 0.5 daycampaign between lots
After a campaign Preparation of 1–2 hours sampling
After a campaign Column unpacking, 1 day Two persons exchange of spare half a day parts etc.
After a campaign Cleaning after use 1 day Two persons and sampling half a day, includes (Column can be after use preparation of cleaned and CIP solutions stored until batch release)
After a campaign QC assays 0.5–1 day Depends on if assays for several instuments are run at the same time
After a campaign Cleaning report 1 hour Includes review
Before sampling can commence, all sampling glasses must be
washed, the column emptied, tube cleaned, and the system
drained. Both column and systems need to be dry prior to swab
sampling. The cleaning procedure also includes the analytical
assays, reviewing results and approving each assay. At CMC, the
number of hours spent on this part of the procedure is estimated
to between a half and one working day (Tables 1 and 2).
The bottleneck in the cleaning verification process is the time
taken for assay results to be ready. Preliminary bioburden results
can be read 3 days after sampling, but a final result is not available
until after 5 days (Fig 1).
Figure 1. Overview of sampling and response times for cleaning results at CMC.
Conventional vs single-use
For a production campaign using conventional chromatography
equipment, the total time needed to clean a system is 6-7 man
days (Table 1) and for a column 5-6 man days (Table 2). However,
the equipment is not ready for use in another production
campaign until the results from the post-campaign cleaning are
approved, which is least 5 facility days (Fig 1).
Although the tables estimate the time taken for each cleaning
step, they do not take into consideration time for handling failed
cleanings and deviations. There is always a risk of this happening
during either the cleaning itself or during QC. The consequence of
a failed cleaning is that time has to be spent on evaluation and
follow up of errors. In a worst case scenario, part of the cleaning
or QC work may have to be repeated. Extra time for failure is not
included in production schedules and can thus affect production
capacity. Within the industry, the average failure rate for cleaning
is about 10%.
On the other hand, employing single-use columns and systems
offers a number of distinct advantages that save facility time.
ReadyToProcess columns are pre-packed and pre-sanitized,
so there is no need for column packing or cleaning procedures
pre- and post-campaign. As a consequence, the risk of a cleaning
failure and any subsequent rescheduling of production is avoided,
and the amount of documentation and analysis in the cleaning
process is reduced. By their nature, single-use products also
remove the risk of cross-contamination.
Table 1. Steps and time allocated to preparing and cleaning a chromatography system. Note that in this study, specific time and costs for preparation of CIP solutions are considered negligible in relation to facility costs.
Table 2. Steps and time allocated to preparing and cleaning a chromatography column. Note that in this study, specific time and costs for preparation of CIP solutions are considered negligible in relation to facility costs.
-
18 Upstream and Downstream • Issue 2
35
30
25
20
15
10
5
0
30% increasein maximum
no. of batches
4 daysChange- over time
7 daysChange- over time
7 daysChange- over time
4 daysChange- over time
14 days production campaign
7 days production campaign
No.
Pro
duct
ion
batc
hes
per y
ear
≈20% increasein maximum
no. of batches
Turning downtime into uptime
Clearly there is an opportunity to increase production capacity
when time-consuming procedures such as cleaning and cleaning
verification can be eliminated. From the data presented in
Tables 1 and 2, based on routines at CMC and data modelling
based on ReadyToProcess technical specifications, single-use
products offer the possibility to turn downtime into uptime. For
a facility with a 49-week production schedule (3 weeks allocated
Figure 2. Estimated increase in the number of batches in a 14-day and 7-day production campaign schedule with single-use products.
to maintenance and calibration) and production campaigns
of 14 days, removing cleaning steps can mean a reduction in
change-over from 7 to 4 days, which would increase the number
of batches produced per year from 16 to 19. For 7-day production
campaigns, the same reduction in change-over time would
increase the maximum number of batches per year from 24 to 31,
or by more than 30% (Fig 2).
Single-use products will benefit multi-product facilities that
demand a fast change-over between production campaigns. This
is particularly important for facilities where the upstream capacity
is larger than the downstream capacity, for example where both
microbial fermentation and mammalian cell culture bioreactors
deliver harvest to the same downstream production line.
Choice for early clinic
By eliminating some of the cleaning steps in a campaign
production scheme, capacity can be increased as non-productive
days become productive. In cases where rapid facility change-
over is demanded, single-use products will be especially useful.
The ReadyToProcess platform will be a good choice for early
clinical phases or for potent products. A standard design and
fixed column sizes packed with a few “standard” media makes
the concept valuable for many applications and a faster route to
market.
CMC Biologics
CMC is a contract manufacturing organization with manufacturing facilities in Europe (CMC Biologics A/S) and the USA (CMC ICOS Biologics Inc) offering a wide range of integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. CMC’s headquarters are located in Copenhagen, Denmark, part of the Medicon Valley region. Its US facility is based in Seattle, WA.
The range of services offered for both mammalian cell culture and microbial fermentation includes the following:
• Process development and scale-up of protein processes
• Production of biopharmaceuticals for: pre-clinical, clinical trial phase I, II, III, and market supply
• Consultancy in facility design, quality and regulatory issues
• New technology evaluation
• Analytical Development & Quality Control
Core skills include fermentation, recovery, purification, analysis and control, quality assurance, Current Good Manufacturing Practice (cGMP) and regulatory matters, as well as facility management, process development, scale-up and technology development.
The company also has a significant network embracing industrial, equipment vendor, academic and public authority contacts. This ensures that it is fully aware of the latest technologies and trends, enabling it to provide unbiased advice to clients.
-
Online Technical Support now includes Filtration ProductsQuickly find what you are looking for
Simple navigation, many illustrations, and a dedicated search
function ensure that you find what you are looking for in a matter of
seconds. Site contents include:
• Filter, column and system recommendations
• Filter, column and system spare parts, tubing kits, connectors, and accessories
• Technical specifications, Application information and Selection guides
• Preparation, operating, testing, and storage procedures for filters and columns
• Troubleshooting and FAQs
• Certificates for filters, chemical products and chromatography hardware
Fast Trak UNICORN™ 6 eCourse (eSYS6)
Direct answers to filtration and chromatography questions
We’ve gathered our filtration and chromatography technical support
onto one single portal. This minimizes the time spent chasing answers
to questions about spare parts and accessories, materials, running
and testing methods, and other similar topics. This extension of Online
Technical Support focuses on filtration products including hollow fiber
cartridges, Kvick™ cassettes, ULTA™ normal flow filters, and systems.
���������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
�������������
�������������������������
���������������������������������������������������������������������������������������������������������������������������������������
������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
�������������������������������������������������������������� ������������������������������������������������������������������������������������������� ���������������������������������������������������������������������������������������������������������������������� ���������������������������������������������������������������������� �������������������������������������������������������������������������������������������������������������������������������������������������������������������� ���������������������������������������������������������������������������������������������������������������������������������������
�������������������� ������������������������������������������������������������������������� �������������������������������������������������������������������������������������������������������������������������������� ����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
����������������������������������������������������������������������������� �����������������������������������������������������������
�� ���������������������������������������������������������������� ���������������������������������������������
������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
�������������������������������������������������������������������������������
Fast Trak Education is one means by which GE Healthcare shares its
unique insights and experience of downstream purification processes.
With over 20 years experience, Fast Trak Training & Education
can provide you with the highest level of training for bioprocess
development and manufacturing.
Online via the Fast Trak Education Gateway
The new ÄKTA™ avant is controlled by UNICORN 6 and includes many
advances and convenient features. To help you exploit these
developments, the online UNICORN 6 eCourse (eSYS6) is available
through the Fast Trak Education Gateway. This course provides an
overview for beginners as well as for users of earlier versions of
UNICORN that need to become acquainted with UNICORN 6.
UNICORN 6 eCourse is structured into logical modules, and includes
interactive step-by-step tutorials on how to perform tasks.
-
20 Upstream and Downstream • Issue 2
Although conventional chromatography columns can be packed reproducibly with repeated practice, it may take several attempts to get the first optimal pack. AxiChrom columns with Intelligent Packing – preprogrammed packing methods and dynamic axial compression – can be packed successfully at the first pack. Extensive training is not required. The Wizard in the UNICORN™ control or AxiChrom Master guides the operator through the relevant steps.
AxiChrom™ platform takes column packing off the critical pathColumn chromatography is the major purification technique used in the production of biological compounds and column packing is
a central and critical element that can be both time and resource
consuming. Repacking, especially at large-scale, is expensive - labor,
buffer, and water costs, as well as attrition of media, are all reasons
to ensure the column is packed optimally the first time. Likewise,
downtime for maintenance adds to costs if equipment needs to be
moved or access to parts is difficult. The AxiChrom column platform
addresses these issues and brings simple operation and superior
performance to column chromatography through Intelligent
Packing, intuitive handling, and predictable scale-up.
Simple operation, superior performance
Perfecting column packing and removing it from the critical path has
been one of the driving forces for the development of the AxiChrom
platform. Intelligent Packing provides verified preprogrammed packing methods, primarily for BioProcess™ media. Packing is
controlled via a wizard in UNICORN for columns connected to an
ÄKTAexplorer™, ÄKTApilot™ or ÄKTAprocess™ system. For larger
columns, the packing procedure is guided from the AxiChrom
Master via its interactive user-interface. Operation is easy and
straightforward, saving time by avoiding repacking, and facilitating
a quick change to different media and creation of new methods.
All the operator needs to do is enter the packing variables and
follow the guidance from UNICORN wizard or the AxiChrom
Master. The axial packing is accurate and reproducible, and less
dependant on the operator’s experience, which facilitates transfer
of methods between facilities and faster product changeover
within a facility.
Intuitive handling guides users through key process of priming, packing, unpacking and maintenance. Checklists in the AxiChrom
Master or a summary page in the UNICORN method wizard ensure
that the correct procedures are followed, thereby reducing the
introduction of errors and saving time. Such clear, interactive
instructions facilitate the development and implementation
of SOPs. Additionally, the novel design with a pivot or swing-
out column tube provides easy access to all relevant parts for
maintenance in situ. No hoists or heavy lifting is required.
-
0.40
0.30
0.20
0.10
AU
0.70
0.60
0.50
0.00
0 20 40 60 80 100 120 min
Lactoferrin
BSA
AxiChrom 70
ReadyToProcess 10
AxiChrom 400
AxiChrom 1000
Column range
AxiChrom columns range from 50 mm in diameter to 1000 mm with tube lengths of 300 or 500 cm. The column tubes are acrylic or glass. AxiChrom up to 200 mm diameter can be operated from ÄKTAexplorer, ÄKTApilot or ÄKTAprocess system. Larger diameters can be operated from the AxiChrom Master or ÄKTAprocess. The AxiChrom Master can operate up to 10 columns.
Predictable scale-up and tech transfer is assured due to the design of the liquid distribution system that was developed using analytical and computational fluid dynamic (CFD)
modeling tools. HETP tests and dye tests (Fig 1) confirm consistent chromatographic
performance across the range of AxiChrom column sizes. The results of model protein
elution tests across the AxiChrom range of columns are shown in Figure 2. BSA and
Lactoferrin can be separated on SP Sepharose™ Fast Flow with the same elution pattern.
The BSA and Lactoferrin peaks are also eluted at the same positions in the gradient in all
column sizes.
Sanitary designAxiChrom columns meet the high standards of sanitary design for cGMP production.
For example, the efficiency of microbial sanitization and endotoxin clearance has been
investigated by challenge testing. Columns packed with Sepharose Fast Flow media were
challenged with E. coli and endotoxins and incubated for 16 to 20 h at room temperature before being treated with 1 M sodium hydroxide (NaOH) and then sampled.
Despite high levels of microbial contamination, no challenging organisms were found after
treatment. In addition, 1 M NaOH gave a 6-log reduction of endotoxin concentration. The
final level in the column flowthrough was less than 0.05 EU/ml, which is below the USP
recommendation for water for injection.
SummaryAxiChrom columns support lean-enabling practices in downstream processing. Intelligent
Packing, intuitive handling and predictable scale-up improve efficiency in column handling
and operation, make column chromatography a less critical element, as well as safer, easier
and more efficient. Compatibility with new-generation, high-flow agarose separation media
is excellent and materials of construction fulfill stringent regulatory requirements for cGMP.
Fig 2. Chromatograms from a scale-up study on AxiChrom 70, 400, and 1000 columns, as well as a ReadyToProcess™ 10 column, showing strong overlap in BSA and Lactoferrin peaks.
Fig 1. Dye tests performed on AxiChrom columns confirm the even distribution through the packed bed.
-
22 Upstream and Downstream • Issue 2
CSL Bioplasma, Australia’s national plasma fractionator, was able to simulate and evaluate a new cleaning method for cassettes using ÄKTAcrossflow. The system, controlled by UNCORN™, enabled the team to simulate a full year’s exposure of the cassette to cleaning and helped reduce evaluation time down to a matter of days.
Evaluating filter cleaning conditions using ÄKTAcrossflow™
CSL Bioplasma has been Australia’s national fractionator of plasma-derived therapeutics since 1952. Plasma voluntarily donated by Australians and collected by the Australian Red
Cross Blood Service is used to produce essential products such as albumin, IgG and clotting
factors. CSL Bioplasma also performs toll fractionation of locally collected plasma from
New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.
The CSL Bioplasma facility, located at Broadmeadows in Victoria, Australia, is a unique
state-of-the-art chromatographic plasma fractionation facility. It is the only commercial
scale facility of its type and one of the most sophisticated plasma fractionation facilities in
the world.
Like all respected biopharmaceutical manufacturers, CSL appreciates that the critical factors
of its production processes are reliability and cost-efficiency. Therefore the CSL Bioplasma
Research & Development team led by Dr. Joseph Bertolini investigated upgrading their
sodium hydroxide (NaOH) based cross flow filtration cleaning protocol to include sodium
hypochlorite (NaOCl) to maximize flux rate and extend filter life.
Simulating a full production year
An important part of the validation requirement to justify a manufacturing change was
confirmation of the chemical compatibility of the cross flow filters with NaOCl. To achieve
this, members of the team, Dr Owen Tatford, Dr Chor Sing Tan and Gerard Seneviratne,
simulated a full production year of cassette exposure to cleaning cycles in the laboratory.
One cassette was subjected to 50 cleaning cycles with NaOH alone and another to
50 cleaning cycles with NaOH supplemented by NaOCl. Cassette integrity was assessed
throughout by normal water permeability (NWP) testing.
Normally it would take months to perform 100 cross flow filtration cleaning cycles manually,
assess the membrane performance and evaluate the data. However, in collaboration
with GE Healthcare Australia, the CSL team was able to use the ÄKTAcrossflow system to
undertake this work.
-
UNICORN facilitated knowledge transfer
The ÄKTAcrossflow system is a cross flow filtration workstation controlled by UNICORN
software. The system monitors and captures sensor data and real-time parameter trends.
All results are captured and reported automatically, making it ideal for handling the large
number of runs performed during this trial.
Although the team’s members had no direct experience with the ÄKTAcrossflow system, they
were experienced ÄKTA chromatography users. Dr Chor Sing Tan was readily able to program
the required method. “Because of my experience with the other UNICORN controlled systems
we have here in the lab, it was straightforward to write a filtration method for our project”
commented Dr Tan.
50 cycles in 5 days
The project had a set time-frame, so the CSL team needed to move quickly to perform the
experiments. “We initially assessed filter integrity by performing an NWP every 3 cleaning
cycles. However we later decided that an NWP every 10th cycle would suffice. As the
cleaning was performed at elevated temperature, we set up a water bath on a timer, hit
run on the ÄKTAcrossflow and left the lab. The system completed its programmed cycles
unattended overnight and the timer turned off the water bath. The next morning, we used the
ÄKTAcrossflow to perform the NWP test and continued with more cleaning cycles. To achieve
the repeat cycles within the time-frame using a manual system would have been impossible”
explained Dr Tatford. “By testing the cassette every 3 cycles, 50 cycles were completed in
30 days, but by testing every 10 cycles the same was achieved in 5 days”.
Supporting the use of NaOCl
The studies established that both cleaning protocols maintained NWP within CSL’s
manufacturing limits and no loss of cassette integrity was observed. This data contributed to the
justification required for allowing the use of the NaOCl procedure in the manufacturing process.
The benefit of using ÄKTAcrossflow for the evaluation study was summed up by Dr Tatford. “The
ÄKTAcrossflow was the key for us achieving our objectives. We fired it up, programmed in what
we wanted it to do and walked away. The evaluation and method wizards were excellent”.
Dr Chor Sing Tan and Dr Owen Tatford in front of the UNICORN controlled ÄKTAcrossflow system that they used in the simulation study on filter cleaning.
Further information
CSL Bioplasma is part of CSL Limited headquartered in Melbourne Australia.
The CSL Group includes:
• CSL Bioplasma incorporating Immunohaematology
• CSL Biotherapies
• CSL Behring incorporating ZLB Plasma
The group has major facilities in Australia, Germany, Switzerland, and the USA. CSL employs over 9000 in 27 countries.
CSL’s key businesses are Research & Development, Plasma Products, Vaccines and Pharmaceuticals.
-
24 Upstream and Downstream • Issue 2
The recent acquisition of MicroCal LLC brings important analytical tools into the GE Healthcare portfolio
When proteins are developed as therapeutics, an important consideration is both the inherent
conformational stability of the protein and the long-term stability of the drug product. Efficient process
development must deliver a predictable, stable and reliable process in a short period of time. What
makes this task particularly challenging is that increasing product purity removes the protein from its
stable environment. In the development of protein purification processes, the stability of the protein to
process conditions, reversibility of conformational changes, and tendency to aggregate are dependent
on pH, buffer composition, and many other factors. Understanding these effects and trends helps when
selecting process conditions. Differential Scanning Calorimetry (DSC) can rapidly identify stabilizing buffer
conditions for chromatography loading and elution, and this information can be used to increase yield
and productivity. Furthermore, DSC data can be used to study the thermal stability of a protein under
different solvent conditions to predict protein stability during long-term storage at lower temperatures
since there is often a correlation between these two properties.
The VP-Capillary DSC system is well suited for downstream bioprocessing applications with a focus on
96–well plate format and automation, allowing analysis of up to 50 different samples in a 24 hour period.
Stability as a predictive tool during bioprocessing
-
THE DEVELOPMENT OF THERAPEUTIC ANTIBODY PRODUCTS
Report Available: Fall 2009
BioProcess Technology Consultants, Inc. and GE Healthcare, Inc. are pleased to announce the upcoming publication of their
defi nitive report on the Chemistry, Manufacturing, and Control (CMC) activities related to monoclonal antibody product
development from initial discovery through first-in-man clinical trials. Anyone involved in the creation, manufacture, and
testing of new therapeutic monoclonal antibodies will benefi t from this timely and valuable information.
Drawing on BioProcess Technology Consultants’ and GE Healthcare’s extensive knowledge and experience in this field,
this report provides a comprehensive review of the technical details of all CMC activities necessary to develop monoclonal
antibody products. The report also provides a detailed analysis of the current regulatory requirements necessary to successfully
develop therapeutic monoclonal antibody product from initial discovery through first-in-man clinical trials along with an
overview of the strategic and regulatory considerations for late-stage product development and commercialization, including a
detailed discussion of such important issues as process validation, Quality by Design, and the risks and benefits associated with
the use of platform processes. The report covers standard as well as new technologies available for all CMC activities related
to monoclonal antibody product development and also addresses such critical activities as process development, including
time-saving, rapid high-throughput experimental approaches to process characterization and optimization, manufacturing
strategies, bulk antibody and finished dosage manufacturing, and process economics. This report goes beyond other reports
or texts by incorporating the latest developments and by integrating regulatory considerations.
0
2
4
6
8
10
12
14
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
Total Biologics including MAbs
MAbs and MAb-related products
Annual US Approval of Recombinant Biologic and
Monoclonal Antibody
Sam
ple
fi g
ure
This 300+ page report will be available in hard copy and electronic
format and will include chapters covering the following:
• Introduction• Discovery• Overview of CMC Activities
• Analytical Methods and Characterization
• Cell Line Development and Engineering
• Cell Culture Development
• Recovery and Purification Development
• High-throughput Technologies
• Formulation Development
• Drug Substance Manufacturing
• Drug Product Manufacturing
• Stability• Process Validation• Regulatory Considerations
• Manufacturing Strategy
• Process Economics
For more information, or to preorder your report, contact BioProcess Technology Consultants at:
Telephone: 978.266.9101 or Email: [email protected].
Or use the pre-order form below and fax your report order to 978-266-9152.
Pre-Order Price: $995 (until October 31, 2009)
Order Price: $1,495 (after November 1, 2009)
Expected Release Date: November 2009
Cells
& d
ebris
Prot
eins
Proc
ess-
relat
ed
Prod
uct-r
elate
d
DNA
Endo
toxin
sVi
ruse
sM
icrob
es
Cell & debris separation
Capture purification
Low pH hold
Intermediate & polishing purification
Virusremoval filtration
Concentration & buffer exchange
Bioburden reduction
Cell culturesupernatant
Bulk drugsubstance
Basic Elements of a Platform Monoclonal
Antibody Purification Processes
Announcement
-
26 Upstream and Downstream • Issue 2
When tailor-made is the best purification solutionWhen standard chromatography media cannot provide the optimal purification solution, Custom Designed Media (CDM) from GE Healthcare can often be the swiftest way to a robust and economic process for your biopharmaceutical.
-
0
200
400
600
800
1000
1200
1400
0 1 2 3 4Pressure (bar)
Capto MMC
Sepharose 6 Fast Flow
Velo
city
(cm
/h)
Further information
Data File Capto Phenyl (high sub), Capto Butyl, Code No. 28-9558-57
Other recently introduced CDM media include: Capto Blue, Data File, Code No. 28-9392-46 KappaSelect, Data File, Code No. 28-9448-22 IgSelect, Data File, Code No. 28-9257-92 VIIISelect, Data File, Code No. 28-9662-37
Brochure When nothing else works: Custom Designed Media, Code No. 28-9279-40
Web www.gelifesciences.com/cdm
Suboptimal processes and/or inadequate purity may be due to inefficient chromatography. In turn, this may be due to the ligand being used, the linker arm, the
porosity of the matrix, or even a combination of all three. In these situations, process
productivity suffers. The CDM service from GE Healthcare can help overcome such
inefficiencies by tailoring a chromatography medium to your specific processing needs
Libraries of proprietary mixed-mode ligands help manufacturers find a suitable selectivity.
Linker arms and coupling chemistries can be varied from low to high density and from
short spacers to long dextran polymers. A range of base matrices offers a wide choice of
porosities and particle sizes. The outcome will be an optimized purification process with
productivity and economy to match.
New media in cooperation with Bio Affinity Company
A recent news item is GE Healthcare’s cooperation with the Bio Affinity Company (BAC)
for developing new affinity media using a proprietary single-chain antibody fragment
technology. BAC’s products (based on Camelid-derived, single-domain antibody
fragments) are used for purifying biopharmaceuticals or scavenging process impurities.
Their combination of stability, affinity, and selectivity helps reduce purification costs and
gives a higher quality product plus increased process flexibility.
Tried and tested project model with proven results
CDM projects are run according to a well-established and proven model where GE
Healthcare specialists work in close collaboration with manufacturers (usually under a
confidentiality agreement) from initial discussions to bulk delivery of the finished product.
Many media first developed as CDM projects are often later introduced as standard
products.
Two recently launched media for hydrophobic interaction chromatography are
summarized below.
Capto™ Phenyl (high sub) and Capto Butyl
Capto Phenyl (high sub) and Capto Butyl were both developed in collaboration with
biopharmaceutical manufacturers specifically to improve productivity when processing
recombinant proteins. Based on the very rigid, high-flow Capto base matrix, both media
have outstanding pressure/flow properties that reduce process cycle times and increase
productivity. Shorter cycle times also reduce exposure of target proteins to proteases.
The maximum flow velocities for Capto Phenyl (high sub) and Capto Butyl in a one-meter
diameter column with a 20 cm bed height extend up to 600 cm/h with a backpressure
below 3 bar. This is much greater than Sepharose™ 6 Fast Flow in a representative large-
scale situation (Fig 2).
Fig 2. Capto media display better pressure/flow properties compared with Sepharose 6 Fast Flow. Running conditions: BPG™ 300 column (30 cm i.d.), open bed at settled bed height equal to 20 cm with water at 20°C.
High chemical stability
Capto media like Capto Phenyl (high sub) and Capto Butyl are used in the capture and
intermediate stages of protein purification. They display high chemical stability and can
withstand storage at pH 1 to 14 for one week with hardly any leakage. Long-term stability
ranges from pH 3 to 13 and short-term stability from pH 3 to 14.
For cleaning-in-place (CIP) as well as sanitization, protocols that contain 1.0 M sodium
hydroxide should prove to be very effective.
Fig 1. Capto Phenyl (high sub) and Capto Butyl increase productivity in downstream manufacture.
-
28 Upstream and Downstream • Issue 2
Discovered with several elements of chance, and first introduced in 1959, Sephadex
gel filtration has been helping scientists isolate and purify biomolecules for 50 years
in both research and industrial applications. It has become one of the cornerstones
to the life sciences. We are celebrating its golden jubilee this year.
Fifty years of Sephadex™ – a springboard to innovation
In the late 1950s, Swedish chemists Jerker Porath and Per Flodin (Uppsala University and the then Pharmacia company respectively)
were investigating separating proteins by column electrophoresis
in the Uppsala laboratories of Nobel Prize winners Arne Tiselius
and Theodor Svedberg. The story goes that someone forgot to
switch on the electric current prior to an overnight run and the
next morning the two scientists found the proteins separated. On
the suggestion of Flodin, Porath conducted further experiments
using cross-linked dextran in the column – dextran was previously
discovered by Björn Ingelman in 1941. Following these successful
experiments, Sephadex was born.
Arne Tiselius suggested gel filtration as the name for the
phenomenon: it emphasized the use of a gel, indicated the main
mechanism (separation according to molecular size [rather than
electric charge]), and was considered concise.
In the June 1959 issue of Nature, Porath and Flodin published their
now classical paper Gel filtration: a method for desalting and group separation.1 The new product, an epichlorohydrin cross-linked dextran gel, was named Sephadex (Separation Pharmacia Dextran).
The first two commercial products, introduced by Pharmacia
in 1959, were Sephadex G-25 and Sephadex G-50. Such was
the interest that stock levels were depleted within two weeks of
launch. The following years also saw thousands of publications
using Sephadex for the isolation and study of biomolecules, and
Sephadex rapidly became one of the most recognized and reliable
brands in labs around the world.
Immediate scientific and commercial impact
Sephadex arrived at the right time. The speed and simplicity of
gel filtration with Sephadex contrasted strongly with most of the separation techniques then available and gave a reproducible,
quantitative means of separating and recovering even sensitive
biological molecules. Enzymes, hormones and other biomolecules
were the subject of intense research and many of the fundamental
chemical processes of life were being elucidated. In industry,
Sephadex ion exchangers were fundamental in the processes to
produce highly purified insulin. Milk proteins, plasma albumin,
immunoglobulins and blood clotting factors were other early
industrial applications.
From Sephadex to ÄKTA™ avant
Sephadex has been the springboard to numerous innovations
within the life sciences. Many of today’s modern tools can trace
their heritage back to this early product, such as the Capto™ and
MabSelect™ media families, the advanced AxiChrom™ column
range, and ÄKTA system platform.
GE Healthcare continues to develop the tools and technologies
needed to investigate biomolecules and bring new therapies to
market – investing in novel solutions that will make their mark on
the next 50 years of innovation.
Per FlodinJerker Porath
Björn Ingelman
1. Porath, J. and Flodin, P. Gel Filtration: A Method for Desalting and Group Separation. Nature 183, 1657–1659 (1959).
Achieving operational efficiencyToolsSolutions for efficiencyModern mediaOperational excellence
High-throughput process development for increased process understandingPreDictor platesAssist software for PreDictor platesScreening conditionsAdsorption isothermsMore knowledge – less time
HiScreen columns – the next stepApplication
ÄKTA™ avant with UNICORN™ 6 accelerates process developmentFlexible system for fast separa